ARTICLE | Company News
Synta cancer news
September 16, 2013 7:00 AM UTC
Synta launched its Hsp90-inhibitor drug conjugate (HDC) platform for cancer therapies. HDCs consist of an inhibitor of heat shock protein 90 (Hsp90) joined to a payload via a cleavable chemical linke...